Ambroxol lozenge bioavailability - An open-label, two-way crossover study of the comparative bioavailability of ambroxol lozenges and commercial tablets in healthy Thai volunteers

被引:9
|
作者
Rojpibulstit, M [1 ]
Kasiwong, S [1 ]
Juthong, S [1 ]
Phadoongsombat, N [1 ]
Faroongsarng, D [1 ]
机构
[1] Prince Songkla Univ, Fac Pharmaceut Sci, Songkhla, Thailand
关键词
D O I
10.2165/00044011-200323040-00007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To compare the bioavailability of two 15mg ambroxol lozenges with a commercial 30mg ambroxol tablet. Design: Open-label, two-way crossover study. Method: Each formulation was randomly administered to 20 healthy Thai volunteers (ten male and ten female) with a 1-week washout period between formulations. After administration, serial blood samples were collected over a 24-hour period and the plasma concentration of ambroxol was subsequently measured using high performance liquid chromatography with ultraviolet detection after liquid-liquid extraction. Pharmacokinetic parameters were analysed by a noncompartmental pharmacokinetic model and compared between formulations using analysis of variance with a significance level of 0.05. Results: The point estimates (90% CI) of the area under the plasma concentration-time curve (AUC) and peak plasma concentration (C-max) ratios between lozenge and commercial tablet were 1.07 (0.89 to 1.28) and 1.20 (1.04 to 1.40), respectively. The point estimate (90% CI) of the difference between formulations for time to C-max was 0.40 (-0.20 to 1.00). Conclusion: The two formulations under test were not bioequivalent based on the stipulated bioequivalence criteria. The biclavailability from the ambroxol lozenge might be better, since the 90% CI of the AUC(0-infinity) fell outside the bioequivalence range, and its range was narrower. The difference in rate of absorption was not conclusive because ambroxol was delivered from the lozenge by two parallel processes, namely absorption via oral and gastrointestinal mucosa. The additional oral mucosal absorption might not only contribute more absorption but also introduce variability compared with that of tablet administration. The relative importance of oral versus gastrointestinal mucosal absorption of ambroxol from the lozenge formulation, and the clinical significance of this, requires further study.
引用
下载
收藏
页码:273 / 280
页数:8
相关论文
共 50 条
  • [41] Pharmacokinetics and Bioequivalence Evaluation of Two Losartan Potassium 50-mg Tablets: A Single-Dose, Randomized-Sequence, Open-Label, Two-Way Crossover Study in Healthy Chinese Male Volunteers
    Jia, Jing-Ying
    Zhang, Meng-Qi
    Liu, Yan-Mei
    Liu, Yun
    Liu, Gang-Yi
    Li, Shui-Jun
    Lu, Chuan
    Weng, Li-Ping
    Qi, Yu-Lin
    Yu, Chen
    CLINICAL THERAPEUTICS, 2010, 32 (07) : 1387 - 1395
  • [42] A novel amorphous preparation improved curcumin bioavailability in healthy volunteers: A single-dose, double-blind, two-way crossover study
    Sunagawa, Yoichi
    Miyazaki, Yusuke
    Funamoto, Masafumi
    Shimizu, Kana
    Shimizu, Satoshi
    Nurmila, Sari
    Katanasaka, Yasufumi
    Ito, Masashi
    Ogawa, Tatsuya
    Ozawa-Umeta, Hitomi
    Hasegawa, Koji
    Morimoto, Tatsuya
    JOURNAL OF FUNCTIONAL FOODS, 2021, 81
  • [43] Effects of food on the bioavailability of gepirone from extended-release tablets in humans: Results of two open-label crossover studies
    Fabre, LF
    Timmer, CJ
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2003, 64 (08): : 580 - 598
  • [44] An open-label, two-period, crossover study of the systemic bioavailability in healthy women of clindamycin phosphate from two vaginal cream formulations
    Levinson, RS
    Mitan, SJ
    Steinmetz, JI
    Gattermeir, DJ
    Schumacher, RJ
    Joffrion, JL
    CLINICAL THERAPEUTICS, 2005, 27 (12) : 1894 - 1900
  • [45] Pharmacokinetics, bioavailability, and bioequivalence of lower-sodium oxybate in healthy participants in two open-label, randomized, crossover studies
    Chen, Cuiping
    Jenkins, Jack
    Zomorodi, Katie
    Skowronski, Roman
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2021, 14 (06): : 2278 - 2287
  • [46] Bioavailability of two oral formulations of loratadine 20 mg with concomitant ketoconazole:: An open-label, randomized, two-period crossover comparison in healthy Mexican adult volunteers
    Piñeyro-López, A
    Piñeyro-Garza, E
    Torres-Alanís, O
    Reyes-Araiza, R
    Silva, MG
    Wacksman, N
    Rangel, RL
    de Lago, A
    Trejo, D
    González de la Parra, M
    Namur, S
    CLINICAL THERAPEUTICS, 2006, 28 (01) : 110 - 115
  • [47] Comparative Bioavailability of Lornoxicam as Single Doses of Quick-Release Tablet, Standard Tablet and Intramuscular InjectionA Randomized Open-Label, Crossover Phase I Study in Healthy Volunteers
    Susanna Radhofer-Welte
    Peter Dittrich
    Marija Simin
    Poul Erik Branebjerg
    Clinical Drug Investigation, 2008, 28 : 345 - 351
  • [48] Relative Bioavailability of Tizanidine Hydrochloride Capsule Formulation Compared with Capsule Contents Administered in Applesauce: A Single-Dose, Open-Label, Randomized, Two-Way, Crossover Study in Fasted Healthy Adult Subjects
    Henney, Herbert R., III
    Fitzpatrick, Anthony
    Stewart, Johnston
    Runyan, Jacob D.
    CLINICAL THERAPEUTICS, 2008, 30 (12) : 2263 - 2271
  • [49] Comparative bioavailability of lornoxicam as single doses of quick-release tablet, standard tablet and intramuscular injection - A randomized, open-label, crossover phase I study in healthy volunteers
    Radhofer-Welte, Susanna
    Dittrich, Peter
    Simin, Marija
    Branebjerg, Poul Erik
    CLINICAL DRUG INVESTIGATION, 2008, 28 (06) : 345 - 351
  • [50] Erratum to: Increased bioavailability of phenylephrine by co-administration of acetaminophen: results of four open-label, crossover pharmacokinetic trials in healthy volunteers
    Hartley C. Atkinson
    Ioana Stanescu
    Isam I. Salem
    Amanda L. Potts
    Brian J. Anderson
    European Journal of Clinical Pharmacology, 2015, 71 : 771 - 772